Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4399Urinary Bladder Neoplasms 1078Carcinoma, Renal Cell 1041Kidney Neoplasms 567Breast Neoplasms 453Neoplasms 403Carcinoma, Transitional Cell 299Neoplasm Metastasis 250Lung Neoplasms 242Testicular Neoplasms 202Melanoma 195Colorectal Neoplasms 193Ovarian Neoplasms 163Carcinoma, Non-Small-Cell Lung 150Sarcoma 135Non-Muscle Invasive Bladder Neoplasms 135Pancreatic Neoplasms 124Colonic Neoplasms 121Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Wilms Tumor 108Recurrence 106Motor Activity 100Stomach Neoplasms 89Urologic Neoplasms 88Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 79Adenocarcinoma 79

Interventions

apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × High-Risk and Oligometastatic Prostate Cancer × Genitourinary × Clear all
NCT04997252 2024-03-18

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

Zhujiang Hospital

Phase NA Unknown
50 enrolled
Genitourinary

High-Risk and Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡